Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>Following the 2023 divestiture of its applied sciences and enterprise services businesses, the company, now named Revvity, has sharpened its focus on the higher-growth, higher-margin life sciences and diagnostics markets.</li>
  <li>Recent financial performance has been challenging, with multi-year declines in key growth metrics. However, the strategic pivot is intended to accelerate organic growth and improve profitability going forward.</li>
  <li>The company is now a pure-play life sciences and diagnostics entity, competing with major industry players by offering integrated solutions in niche areas like newborn screening, immunodiagnostics, and drug discovery research tools.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Following the 2023 divestiture of its applied sciences and enterprise services businesses, the company, now named Revvity, has sharpened its focus on the higher-growth, higher-margin life sciences and diagnostics markets.
  Recent financial performance has been challenging, with multi-year declines in key growth metrics. However, the strategic pivot is intended to accelerate organic growth and improve profitability going forward.
  The company is now a pure-play life sciences and diagnostics entity, competing with major industry players by offering integrated solutions in niche areas like newborn screening, immunodiagnostics, and drug discovery research tools.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: PerkinElmer Inc (PKI UN) - May 2026

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Revvity shares surged over 9% after the health-sciences company raised its 2025 earnings per share outlook above $5.00 and boosted Q4 revenue guidance to $772 million, exceeding Wall Street expectations.</li><li>The company’s preliminary results, released ahead of its presentation at the JPMorgan Healthcare Conference, came as a surprise to a market that had seen RVTY down 9% over the past 12 months.</li><li>Yet, despite the better-than-expected guidance and a solid 2026 margin outlook, investor sentiment remains cautious.</li></ul>

Revvity shares surged over 9% after the health-sciences company raised its 2025 earnings per share outlook above $5.00 and boosted Q4 revenue guidance to $772 million, exceeding Wall Street expectations.The company’s preliminary results, released ahead of its presentation at the JPMorgan Healthcare Conference, came as a surprise to a market that had seen RVTY down 9% over the past 12 months.Yet, despite the better-than-expected guidance and a solid 2026 margin outlook, investor sentiment remains cautious.

Revvity Popped On Earnings Boost—Will Feb. 2 Spark The Next Big Move?

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). </li>
<li>Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).</li>
<li>With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). 
Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).
With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.


Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

<ul><li>Revvity's third-quarter 2025 results demonstrate a stable performance amid a challenging market landscape, with organic growth of 1% that aligned with expectations despite unfavorable forex fluctuations.</li><li>The company's Signals software division proved a strong performer, with 20% organic growth, and their reproductive health segment also showed notable progress.</li><li>However, the Diagnostic segment experienced a significant decline in China due to lingering DRG impacts, though the non-China segment performed robustly, growing in the high single digits.</li></ul>

Revvity's third-quarter 2025 results demonstrate a stable performance amid a challenging market landscape, with organic growth of 1% that aligned with expectations despite unfavorable forex fluctuations.The company's Signals software division proved a strong performer, with 20% organic growth, and their reproductive health segment also showed notable progress.However, the Diagnostic segment experienced a significant decline in China due to lingering DRG impacts, though the non-China segment performed robustly, growing in the high single digits.

Revvity: Can It Reignite Growth With New Product Launches & Strategic Partnerships?

<ul>
<li>We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).</li>
<li>Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold</li>
<li>The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS</li>
</ul>


We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).
Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold
The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS


Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

United States

Revvity, Inc. provides health science solutions, technologies, expertise, and services. The Company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics, and other areas. Revvity serves pharmaceutical and biotech, clinical labs, academia, and governments worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Revvity (RVTY US)

Primer: PerkinElmer Inc (PKI UN) - May 2026

Following the 2023 divestiture of its applied sciences and enterprise services businesses, the company, now named Revvity, has sharpened its...

αSK Primers

Revvity Popped On Earnings Boost—Will Feb. 2 Spark The Next Big Move?

Revvity shares surged over 9% after the health-sciences company raised its 2025 earnings per share outlook above $5.00 and boosted Q4 revenue...

Baptista Research

Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

Mixed Signals in A.I. Names ($SOXX $CHAT $DRAM $WGMI); Bullish Outlook Intact $SPX $QQQ $IWM. $CHAT breaking above the 50-day MA likely signaling...

Vermilion Research

Revvity: Can It Reignite Growth With New Product Launches & Strategic Partnerships?

Revvity's third-quarter 2025 results demonstrate a stable performance amid a challenging market landscape, with organic growth of 1% that aligned...

Baptista Research

Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

Back to Near-Term Bullish on $SPX and Nasdaq 100 $NDX; Crucial Supports Held at 6480-6520 on SPX and $580-$583 on $QQQ, we are near-term bullish as...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)